彭布罗利珠单抗
进行性多灶性白质脑病
医学
中止
免疫抑制
硫唑嘌呤
JC病毒
慢病毒
白质脑病
皮肤病科
免疫学
疾病
免疫系统
内科学
多发性硬化
免疫疗法
作者
Matilde Ørum,Alex Lund Laursen,Anne Troldborg
出处
期刊:Case Reports
[BMJ]
日期:2024-09-01
卷期号:17 (9): e260624-e260624
标识
DOI:10.1136/bcr-2024-260624
摘要
This case report discusses a patient with systemic lupus erythematosus (SLE) treated with low-dose azathioprine who developed progressive multifocal leukoencephalopathy (PML). PML is a rare, severe, demyelinating disease linked to John Cunningham polyomavirus (JCV) reactivation. Treated with pembrolizumab, an immune checkpoint inhibitor, the patient initially improved. However, after the fourth dose, her condition rapidly worsened resulting in treatment discontinuation and death. Similar cases highlight the complex interplay of factors in PML development in SLE patients, including immunosuppression and genetic factors. The use of pembrolizumab in PML and SLE necessitates careful consideration of potential complications.
科研通智能强力驱动
Strongly Powered by AbleSci AI